CSL Shares Fall 20% in Biggest Single-Day Crash Ever
Synopsis
CSL shares fell 20.6% on Monday to $95.19, the biggest single-day drop in the company's history, after interim CEO Gordon Naylor's 90-day review triggered another guidance cut. CSL now expects FY26 revenue of US$15.2 billion and profit of US$3.1 billion, both below FY25. The company flagged US$5 billion in additional non-cash impairments across FY26 and FY27, largely related to the CSL Vifor acquisition. CSL is now down 45 per cent in 2026 and more than 60% over the past year as investors lose patience with repeated downgrades and write-downs.
CSL has just suffered the worst trading day in its history. Shares crashed more than 20% on Monday after the healthcare giant cut its full-year outlook again and warned investors to expect another US$5 billion in write-downs.
Key Highlights
- CSL shares fell 20.6% on Monday, closing at $95.19, the biggest one-day fall the company has ever recorded.
- The stock is now down 45% in 2026 and more than 60% over the past 12 months.
- FY26 revenue guidance has been cut to around US$15.2 billion.
- CSL also flagged another US$5 billion in non-cash impairments across FY26 and FY27.
- Management says it is targeting annual transformation savings of US$500 million to US$550 million by FY28.
CSL Cuts Guidance Again After Interim CEO’s 90-Day Review
Monday’s update came after interim CEO Gordon Naylor completed a 90-day review of the business, and the outcome was far worse than investors had hoped. CSL now expects FY26 revenue to land at around US$15.2 billion on a constant currency basis, with profit after tax and amortisation forecast at roughly US$3.1 billion, excluding restructuring costs and impairments.
Both numbers are below FY25 results, where the company generated US$15.6 billion in revenue and US$3.3 billion in profit. Management admitted that while some of its growth initiatives are gaining traction, the benefits are taking much longer to show up financially than expected.
Why did CSL Fall?
CSL is currently facing several overlapping challenges across key parts of the business.
In the US immunoglobulin market, one of CSL’s largest revenue drivers, demand is still growing at a healthy mid-to-high single-digit pace. However, excess channel inventory built up during the pandemic is now being cleared, which CSL expects will reduce revenue by around US$300 million.
China is also proving difficult. While CSL’s albumin volumes and market share have improved, the overall market value has declined, creating another estimated US$200 million hit to revenue.
The conflict in the Middle East, slower-than-expected uptake of gene therapy treatment Hemgenix, and increased competition in iron treatments are expected to reduce revenue by another US$150 million combined.
Then there are the write-downs.
CSL warned that it expects approximately US$5 billion in additional non-cash pre-tax impairments across FY26 and FY27. These impairments mainly relate to CSL Vifor’s intangible assets, product portfolio, and selected property, plant, and equipment.
The issue is especially painful because CSL acquired Vifor Pharma in 2022 for roughly A$16.4 billion, a deal that has now become a major source of frustration for shareholders as repeated impairments continue to pile up.
Investors Take
The market reaction says a lot about where investor sentiment now stands.
CSL was once considered one of the ASX’s safest and most dependable blue-chip companies, a healthcare for,known for delivering steady earnings growth year after year. Seeing the stock fall more than 60 per cent from its peak in just over a year is an extraordinary move for a business with this kind of scale and reputation.
There were a few positive points buried in Monday’s announcement. CSL Behring is still expected to post revenue growth in the second half, while CSL Seqirus is now tipped to perform modestly better than earlier forecasts suggested.
At the same time, management is continuing with its transformation strategy, targeting annual savings of between US$500 million and US$550 million by FY28 through operational improvements, streamlining the portfolio, and maintaining stricter capital discipline.
FAQs
- How much did CSL shares fall?
CSL shares dropped 20.6% on Monday to $95.19. The stock is now down 45% in 2026 and more than 60% over the past year.
- Why did CSL cut guidance again?
The downgrade was driven by multiple issues, including US immunoglobulin inventory normalisation, weakness in China’s albumin market, slower Hemgenix growth, Middle East disruption, and stronger competition in iron treatments.
- What is behind the US$5 billion impairment?
The write-downs mainly relate to CSL Vifor’s intangible assets and product portfolio following the disappointing performance of the Vifor Pharma acquisition completed in 2022.
Follow Inspirepreneur Magazine for daily global business news.
At Inspirepreneurs Magazine, covering entrepreneurship, business failures, and the human stories behind the world's most ambitious founders. She writes at the intersection of strategy and storytelling.
